Cargando…

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China. Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Hongfu, Xu, Baohua, Li, Na, Zheng, Bin, Zheng, Zhiwei, Liu, Maobai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634950/
https://www.ncbi.nlm.nih.gov/pubmed/34867339
http://dx.doi.org/10.3389/fphar.2021.732912
_version_ 1784608212669956096
author Cai, Hongfu
Xu, Baohua
Li, Na
Zheng, Bin
Zheng, Zhiwei
Liu, Maobai
author_facet Cai, Hongfu
Xu, Baohua
Li, Na
Zheng, Bin
Zheng, Zhiwei
Liu, Maobai
author_sort Cai, Hongfu
collection PubMed
description Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China. Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’s lifetime quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). One-way sensitivity and probability sensitivity analyses were performed to test the stability of the model. Results: Treatment of esophageal squamous cell carcinoma with camrelizumab added 0.36 QALYs and resulted in an incremental cost of $1,439.64 compared with chemotherapy, which had an ICER of $3,999 per QALY gained. The ICER was far lower than the threshold of willingness to pay for one time the GDP per capita in China. Sensitivity analysis revealed that the ICERs were most sensitive to the cost of drugs, but the parameters did not have a major effect on the results of the model. Conclusion: Camrelizumab is likely to be a cost-effective option compared with chemotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma. This informs patient selection and clinical path development.
format Online
Article
Text
id pubmed-8634950
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86349502021-12-02 Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma Cai, Hongfu Xu, Baohua Li, Na Zheng, Bin Zheng, Zhiwei Liu, Maobai Front Pharmacol Pharmacology Background: This study aimed to analyze the cost effectiveness of camrelizumab in the second-line treatment of advanced or metastatic esophageal squamous cell carcinoma in China. Methods: On the basis of the ESCORT clinical trial, a partitioned survival model was constructed to simulate the patient’s lifetime quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). One-way sensitivity and probability sensitivity analyses were performed to test the stability of the model. Results: Treatment of esophageal squamous cell carcinoma with camrelizumab added 0.36 QALYs and resulted in an incremental cost of $1,439.64 compared with chemotherapy, which had an ICER of $3,999 per QALY gained. The ICER was far lower than the threshold of willingness to pay for one time the GDP per capita in China. Sensitivity analysis revealed that the ICERs were most sensitive to the cost of drugs, but the parameters did not have a major effect on the results of the model. Conclusion: Camrelizumab is likely to be a cost-effective option compared with chemotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma. This informs patient selection and clinical path development. Frontiers Media S.A. 2021-11-16 /pmc/articles/PMC8634950/ /pubmed/34867339 http://dx.doi.org/10.3389/fphar.2021.732912 Text en Copyright © 2021 Cai, Xu, Li, Zheng, Zheng and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cai, Hongfu
Xu, Baohua
Li, Na
Zheng, Bin
Zheng, Zhiwei
Liu, Maobai
Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title_full Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title_fullStr Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title_full_unstemmed Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title_short Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
title_sort cost-effectiveness analysis of camrelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634950/
https://www.ncbi.nlm.nih.gov/pubmed/34867339
http://dx.doi.org/10.3389/fphar.2021.732912
work_keys_str_mv AT caihongfu costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma
AT xubaohua costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma
AT lina costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma
AT zhengbin costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma
AT zhengzhiwei costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma
AT liumaobai costeffectivenessanalysisofcamrelizumabversuschemotherapyassecondlinetreatmentofadvancedormetastaticesophagealsquamouscellcarcinoma